INFLUENCE OF DYSLIPIDEMIA ON SOMATIC NEUROPATHY IN TYPE 2 DIABETES MELLITUS

Abstract

Introduction: Dyslipidemia is an established cardiovascular risk factor. But its influence on somatic neuropathy (PNP) in diabetes mellitus is not clear.

Objective of the study: This study assessed the association between lipids and PNP in diabetes mellitus.

Materials and Methods: 101 type 2 diabetics with recently done fasting lipid profile were included. Lipid profile included fasting total cholesterol, LDL- cholesterol, HDL- cholesterol and triglycerides. Based on the neurological examination diabetics were divided into two groups: with PNP (n = 53) and without PNP (n = 48). Severity of PNP was quantified based on total scoring of all the definite clinical signs of PNP. 30 healthy subjects matched for age and sex with PNP group served as control. Statistical analysis was done with suitable statistical tests. Statistical significance was taken to be at p-value less than 0.05.

Results: Mean total cholesterol, triglycerides, LDL cholesterol of PNP group was significantly higher compared to non-diabetic control (p < 0.05; < 0.01; < 0.001 respectively). There was no significant difference in any of the lipids between with PNP and without PNP groups. Among the lipids, correlation was observed only between triglycerides and PNP severity score (r = 0.37, p < 0.01). Mean age and duration of diabetes of PNP group was significantly higher compared to without PNP group (p < 0.01; < 0.01 respectively).

Conclusion: Dyslipidemia persists in type 2 diabetics. Hypertriglyceridemia is correlated with severity of PNP. Higher age and duration of diabetes are associated with PNP in type 2 diabetes.

Keywords

somatic neuropathy - hypertriglyceridemia - dyslipidemia - age - duration - type 2 diabetes mellitus

Publication History

Article published online:
27 June 2020

• References

• 1 Edwards JL, Vincent AM, Cheng HT, Feldman EL. Diabetic neuropathy: Mechanisms to management. Pharmacol Ther 2008; 120:1–34.
• 2 Feldman EL, Stevens MJ, Russell JW, Peltier A, Inzucchi S, Porte JD, Sherwin RS, Baron A. Somatosensory neuropathy. In The Diabetes Mellitus Manual. New York: McGraw-Hill, 2005, p. 366–384.
• 3 Feldman EL. Diabetic neuropathy. Curr Drug Targets 2008; 9:1–2.
• 4 Diabetes Control and Complications Trial Cohort. Epidemiology of Diabetes Interventions and Complications (EDIC): design, implementation, and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial Cohort. Diabetes Care 1999; 22:99–111.
• 5 UK Prospective Diabetes Study (UKPDS) Group. Intensive bloodglucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352:837–853.
• 6 Steiner G. How can we improve the management of vascular risk in type 2 diabetes: insights from FIELD. Cardiovasc Drugs Ther 2009; 23:403–408.
• 7 Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348:383–393.
• 8 Tesfaye S, Chaturvedi N, Eaton SE, Ward JD, Manes C, Ionescu- Tirgoviste C, Witte DR, Fuller JH. Vascular risk factors and diabetic neuropathy. N Engl J Med 2005; 352:341–350.
• 9 Kempler P, Tesfaye S, Chaturvedi N, Stevens LK, Webb DJ, Eaton S, Kerenyi Z, Tamas G, Ward JD, Fuller JH. Autonomic neuropathy is associated with increased cardiovascular risk factors: the EURODIAB IDDM Complications Study. Diabet Med 2002; 19:900–909.
• 10 Wiggin TD, Sullivan KA, Pop-Busui R, Amato A, Sima AA, Feldman EL. Elevated triglycerides correlate with progression of diabetic neuropathy. Diabetes 2009; 58: 1634–1640.
• 11 Jarmuzewska EA, Ghidoni A, Mangoni AA. Hypertension and Sensorimotor Peripheral Neuropathy in Type 2 Diabetes. Eur Neurol. 2006; 57:91–5.
• 12 Temelkova-Kurktschiev T, Hanefeld M. The lipid triad in type 2 diabetes - prevalence and relevance of hypertriglyceridaemia/low high-density lipoprotein syndrome in type 2 diabetes. Exp Clin Endocrinol Diabetes. 2004; 112:75–9.
• 13 Décary S, Dumont G, Lamarche B, Hogue JC, Tremblay AJ, Bergeron J, et al. Assessment of the validity of the frequently used lipid indices for predicting LDL peak particle diameter in a large cohort of 1955 normal and dyslipidemic subjects. Clin Biochem. 2010; 43:401–6.
• 14 Kennedy WR, Navarrho X, Sakuta M, Mandell H, Knox CK, Sutherland DE. Physiological and clinical correlates of cardiorespiratory reflexes in diabetes mellitus. Diabetes Care 1989; 12; 399-408.
• 15 R. Shankar, Shashikiram M, Gopalraj M, Evangeline Nesa Rathnabai. Assessment of serum Triglycerides among diabetes patients with Peripheral Neuropathy. Journal of Medical Research and Practice 2012; 1(3):68-71
• 16 McManis PG, Windebank AJ, Kiziltan M. Neuropathy associated with hyperlipidemia. Neurology. 1994; 44(11):2185-6.
• 17 Dyck PJ, Davies JL, Wilson DM, Service FJ, Melton LJ 3rd, O'Brien PC: Risk factors for severity of diabetic polyneuropathy: intensive longitudinal assessment of the Rochester Diabetic Neuropathy Study cohort. Diabetes Care 199; 22:1479–1486.
• 18 Humphrey AR, Dowse GK, Thoma K, Zimmet PZ. Diabetes and nontraumatic lower extremity amputations. Incidence, risk factors, and prevention—a 12-year follow-up study in Nauru. Diabetes Care 1996; 19:710–714.
• 19 Hania S. Kassem, Sami T. Azar, Mira S. Zantout & Raja A. Sawaya. Hypertriglyceridemia and peripheral neuropathy in neurologically asymptomatic patients. Neuroendocrinol Lett 2005; 26(6):775–779.